Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report

Şeyma Handan AKYÖN; Yeşer GENÇ

doi:https://doi.org/10.46310/tjim.1072232

Article Details

Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report

Authors:

Şeyma Handan AKYÖN | Yeşer GENÇ

Publisher:

Nizameddin KOCA

Main Topics:

Diseases

Journal:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.152-154

Document Type:

Article

Publication Date:

3/2022

Document Language:

English

Document ID (Org No.):

2000637650

Frequency:

Quarterly

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1072232

Abstract:

 

After the pandemic started, vaccines against SARS-CoV-2 were developed and applied in a short time. Later, various side effects were reported during the use of these vaccines. Among the skin side effects, besides local skin reactions at the injection site, urticaria, maculopapular rash and pityriasis rosea-like reactions were observed. We presented a female case who developed pityriasis rosea after administering the 3rd dose of the Pfizer-BioNTech COVID-19 vaccine.

Article Details

Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report

Authors: Şeyma Handan AKYÖN | Yeşer GENÇ

Publisher: Nizameddin KOCA

Main Topics: Diseases

Journal: Turkish Journal of Internal Medicine 2022 Vol.4, pp.152-154

Document Type: Article

Publication Date: 3/2022

Document Language: English

Document ID (Org No.): 2000637650

Frequency: Quarterly

eISSN: 2687-4245

DOI: https://doi.org/10.46310/tjim.1072232

Issues

Authors:

Şeyma Handan AKYÖN | Yeşer GENÇ

Publisher:

Nizameddin KOCA

Main Topics:

Diseases

Journal:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.152-154

Document Type:

Article

Publication Date:

3/2022

Document Language:

English

Document ID (Org No.):

2000637650

Frequency:

Quarterly

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1072232